Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways

Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways

(2017) Zhen Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Chemosensitizing effect of podophyllotoxin acetate on topoisomerase inhibitors leads to synergistic enhancement of lung cancer cell apoptosis

(2016) WAN GI HONG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

(2016) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination treatment with triptolide and hydroxycamptothecin synergistically enhances apoptosis in A549 lung adenocarcinoma cells through PP2A-regulated ERK, p38 MAPKs and Akt signaling pathways

(2015) GUANMIN MENG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer

(2015) Yan Zhu et al.   Scientific Reports

Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect

(2013) Christopher F. Prada et al.   BIOCHEMICAL PHARMACOLOGY

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

(2013) Shuichi Hironaka et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of gastric cancer in Asia: resource-stratified guidelines

(2013) Lin Shen et al.   LANCET ONCOLOGY

Genistein Sensitizes Bladder Cancer Cells to HCPT Treatment In Vitro and In Vivo via ATM/NF-κB/IKK Pathway-Induced Apoptosis

(2013) Yong Wang et al.   PLoS One

Drugging Topoisomerases: Lessons and Challenges

(2012) Yves Pommier   ACS Chemical Biology

In vitro and in vivo anticancer effects of Lithospermum erythrorhizon extract on B16F10 murine melanoma

(2012) Seetharaman Rajasekar et al.   JOURNAL OF ETHNOPHARMACOLOGY

A phase II trial of oral gimatecan for recurrent glioblastoma

(2012) Jethro Hu et al.   JOURNAL OF NEURO-ONCOLOGY

Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer

(2011) Eliza Hawkes et al.   EUROPEAN JOURNAL OF CANCER

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes

(2009) S. Pecorelli et al.   ANNALS OF ONCOLOGY

Clinical pharmacokinetics of the new oral camptothecin gimatecan: The inter-patient variability is related to α1-acid glycoprotein plasma levels

(2009) Roberta Frapolli et al.   EUROPEAN JOURNAL OF CANCER

A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy

(2008) Alexandra Leary et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors

(2008) A. X. Zhu et al.   CLINICAL CANCER RESEARCH